The retrospective study identified the use of IV PPI for inappropriate indications in 72 (50%) of patients with UGIB.
The correct dosing regimen was used in only 25% of patients with UGIB.
In total, IV PPI was used appropriately in terms of dosing and indication in only 21% (95% confidence interval, CI: 14 to 27) of patients with UGIB.
Only 33% of patients without UGIB were truly NPO, and only 51% received the correct dosing frequency.
In total, IV PPI was used appropriately in terms of dosing and indication in only 14% (95% CI: 7 to 22) of patients without UGIB.
A longer time to delay to endoscopy (odds ratio per extra hour 1.06, 95% CI: 1.01 to 1.1; p=0.006) and younger patient age (odds ratio per increased decade 0.72, 95% CI: 0.5 to 0.99; p=0.02) were found to be independently associated with higher inappropriate use of IV PPI in a multivariate analysis.
The multidisciplinary intervention was found to significantly reduce inappropriate prescribing of IV PPI by 26% (95% CI: 10 to 42) among patients with UBIG and by 41% (95% CI: 24 to 58) among patients without UBIG, (p<0.0001 for both).
When the 30 patients whose IV PPI was considered inappropriate and was corrected by pharmacists were included in the analysis, the results were not changed (a reduction of 22%).